Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Table 2 Guidelines/local working group recommendations consulted for diagnosis of relapsed or refractory Ph(–) B-precursor ALL

Guideline or local working group recommendation	Number of respondents consulting for diagnosis, n (%)^a
	France	Germany	Italy	Spain	UK	Total
	N = 15	N = 15	N = 15	N = 15	N = 15	N = 75
ASH/ASCO, US	6 (40)	2 (13)	10 (67)	5 (33)	3 (20)	26 (35)
EWALL, Europe	6 (40)	1 (7)	3 (20)	2 (13)	4 (27)	16 (21)
NCCN, US	3 (20)		7 (47)	4 (27)		14 (19)
GMALL, Germany	1 (7)	8 (53)	1 (7)	1 (7)		11 (15)
GIMEMA, Italy			10 (67)			10 (13)
PETHEMA, Spain				9 (60)		9 (12)
Others^b	3 (20)				1 (7)	4 (5)

^aRespondents could select multiple guidelines
^bThe following guidelines and/or local working group recommendations were consulted by one respondent for diagnosis: HAS, France; Onco LR, France; GELA, France; BCSH, UK
ALL, acute lymphoblastic leukaemia; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; BCSH, the British Committee for Standards in Haematology; EWALL, European Working group for Adult Lymphoblastic Leukemia; GELA, Groupe d’Etude des Lymphomes de l’Adulte (Study Group of the Adult Lymphoma); GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adultodell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German Multicenter Study Group for Adult ALL; HAS, Haute Autorité de Santé (High Authority for Health); NCCN, the National Comprehensive Cancer Network; Onco LR, le réseau régional de Cancérologie en Languedoc Roussillon (regional network of Oncology in Languedoc Roussillon); PETHEMA, Program for Study and Treatment of Malignant Haemopathies, Spanish Society of Haematology

ISSN: 1471-2407